AstraZeneca’s Biologics License Application (BLA) for sonesitatug vedotin (Sone-Ve) has been accepted and granted Priority Review in the US for the 2nd and later-line treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or oesophageal adenocarcinoma (EAC) with Claudin 18.2 (CLDN18.2) expression on at least 25% of tumour cells at any staining intensity.
The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.1 The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the second quarter of 2027.
CLDN18.2 has emerged as an important therapeutic target for these patients, with an estimated 60% of gastric/GEJ cancers expressing CLDN18.2 in 25% or more of tumour cells.2 Each year, there are roughly 7,500 patients in the US treated in the 2nd and later-line setting for advanced or metastatic CLDN18.2-positive, non-HER2-positive gastric/GEJ cancers.3 The majority of patients with gastric/GEJ cancers are diagnosed at an advanced or metastatic stage, where the prognosis is especially poor and treatment options are limited.4 Less than 20% of patients diagnosed at this late-stage survive more than one year.
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: "After progressing on first-line treatment, patients with Claudin 18.2-positive advanced gastric cancer have no targeted options. Sone-Ve is the first ADC targeting Claudin 18.2 to improve overall survival for patients compared to current standard of care in this setting and across a population that encompasses a much broader definition of Claudin 18.2 positivity than for current drugs. This Priority Review of our submission speaks to the significant potential of this medicine and accelerates the ability to bring forward a new targeted approach and alternative to traditional chemotherapy for thousands of patients in the US."
The BLA is based on results from the CLARITY-Gastric01 Phase III trial which were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO).
In the trial, Sone-Ve reduced the risk of death by 42% compared to investigator’s choice of therapy (based on an OS hazard ratio [HR] of 0.58; 95% confidence interval [CI] 0.47–0.73; p=0.000004) in the 2nd- and later line setting. Median OS was 10.6 months for patients treated with Sone-Ve compared to 6.4 months for investigator’s choice of therapy. The OS benefit observed was consistent across most predefined subgroups, including subgroups based on lower or higher CLDN18.2 expression levels.6
The tolerability profile of Sone-Ve was manageable and consistent with its known safety profile with no new safety signals identified. Fewer Grade 3 or higher treatment-related adverse events.6
Sone-Ve has received Orphan Drug Designation from the US Food and Drug Administration and the European Commission for the treatment of gastric and GEJ cancers. It has also received Breakthrough Designation in China for the 2nd-line treatment of gastric cancer. Regulatory applications are currently under review in the EU, China and several other countries based on the CLARITY-Gastric01 results.